COVID vaccine evaluation of barriers and resources among families of children with diagnosed allergies.
COVID-19
allergy
children
family
knowledge translation
vaccine hesitancy
Journal
Frontiers in allergy
ISSN: 2673-6101
Titre abrégé: Front Allergy
Pays: Switzerland
ID NLM: 9918227355906676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
11
2022
accepted:
22
03
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
We aimed to determine vaccine hesitancy and the main barriers associated with the 2019 novel coronavirus, SARS-CoV-2 (COVID-19) vaccination among families of children diagnosed with food/drug/environmental allergies. Between May and June 2021, we approached 146 families seen at the outpatient allergy clinic at the Montreal Children's Hospital and a community allergy practice were invited to complete an anonymous online survey on COVID-19 and vaccination attitudes and behaviour. Uni and multivariable logistic regressions were compared to estimate factors associated with vaccine hesitancy. Among all patients, 24.1% reported vaccine hesitancy. The large majority of parents (95.2%) believed that vaccines work. The most common barrier to vaccination was fear of adverse side effects (57.0%). One-third of participants (31.5%) reported that a history of food, venom and drug allergy was a contraindication for COVID-19 vaccination. Fifty-nine (60.8%) participants stated that the dissemination of additional information would increase their willingness to be vaccinated. Most (96.9%) parents reported that their children's vaccinations were up to date. Hesitant families were more likely to be parents of children aged 6-10 years, be of Asian descent, report that mRNA vaccines are riskier than traditional vaccines, and report that the vaccine should not be given if the child has a history of allergic reaction to vaccines. Vaccine hesitancy exists mainly among certain ethnic groups and families with young children. Allergies to food, venom and drug allergy are commonly perceived as contraindications for COVID-19 vaccination. Knowledge translation activities addressing parental concerns will help increase vaccination rates.
Sections du résumé
Background
UNASSIGNED
We aimed to determine vaccine hesitancy and the main barriers associated with the 2019 novel coronavirus, SARS-CoV-2 (COVID-19) vaccination among families of children diagnosed with food/drug/environmental allergies.
Methods
UNASSIGNED
Between May and June 2021, we approached 146 families seen at the outpatient allergy clinic at the Montreal Children's Hospital and a community allergy practice were invited to complete an anonymous online survey on COVID-19 and vaccination attitudes and behaviour. Uni and multivariable logistic regressions were compared to estimate factors associated with vaccine hesitancy.
Results
UNASSIGNED
Among all patients, 24.1% reported vaccine hesitancy. The large majority of parents (95.2%) believed that vaccines work. The most common barrier to vaccination was fear of adverse side effects (57.0%). One-third of participants (31.5%) reported that a history of food, venom and drug allergy was a contraindication for COVID-19 vaccination. Fifty-nine (60.8%) participants stated that the dissemination of additional information would increase their willingness to be vaccinated. Most (96.9%) parents reported that their children's vaccinations were up to date. Hesitant families were more likely to be parents of children aged 6-10 years, be of Asian descent, report that mRNA vaccines are riskier than traditional vaccines, and report that the vaccine should not be given if the child has a history of allergic reaction to vaccines.
Conclusion
UNASSIGNED
Vaccine hesitancy exists mainly among certain ethnic groups and families with young children. Allergies to food, venom and drug allergy are commonly perceived as contraindications for COVID-19 vaccination. Knowledge translation activities addressing parental concerns will help increase vaccination rates.
Identifiants
pubmed: 37216150
doi: 10.3389/falgy.2023.1101247
pmc: PMC10198258
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1101247Informations de copyright
© 2023 Gooding, Protudjer, Gabrielli, Mulé, Shand, Zhang, McCusker, Noya, Harvey, Chalifour, Sicard, Abrams, Amiel, Ngo, Bonnici, MacDonald and Ben-Shoshan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Vaccine. 2015 Aug 14;33(34):4180-90
pubmed: 25896377
Patient Saf Surg. 2021 May 1;15(1):20
pubmed: 33933145
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478623
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):89-91
pubmed: 33393485
Rheumatol Int. 2021 Jan;41(1):19-32
pubmed: 33219837
J Pediatr Nurs. 2022 Jul-Aug;65:e5-e6
pubmed: 34930655
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767